GlassScriptPhysician profile
Amara U Uzoma
NPI 1679953228
$1,174.70
in general payments reported to CMS, 2019-2025
13 companies · $99.00 in 2025
The $99.00 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $256 · 2021: $14.72 · 2022: $270 · 2023: $238 · 2024: $63.22 · 2025: $99.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.80 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $347.75 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Coopersurgical, INC. | $236.67 | 2020-2022 | |
| Astellas Pharma US INC | $231.63 | 2023-2025 | Veozah, Myrbetriq |
| Genentech, INC. | $109.91 | 2019 | |
| Ethicon US, LLC | $83.32 | 2022-2023 | Enseal |
| Hologic Sales and Service, LLC | $36.68 | 2022 | |
| Organon LLC | $25.21 | 2022-2023 | Nexplanon |
| Sumitomo Pharma America, INC. | $24.97 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2019 | |
| Therapeuticsmd, INC. | $18.08 | 2022 | |
| Agile Therapeutics, INC. | $15.05 | 2024 | Twirla |
| Biogen, INC. | $14.31 | 2024 | Vumerity |
| Amag Pharmaceuticals, INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amara Uzoma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.